Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

23 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase 1 study of nivolumab in combination with interferon-gamma for patients with advanced solid tumors.
Zibelman M, MacFarlane AW 4th, Costello K, McGowan T, O'Neill J, Kokate R, Borghaei H, Denlinger CS, Dotan E, Geynisman DM, Jain A, Martin L, Obeid E, Devarajan K, Ruth K, Alpaugh RK, Dulaimi EA, Cukierman E, Einarson M, Campbell KS, Plimack ER. Zibelman M, et al. Among authors: macfarlane aw 4th. Nat Commun. 2023 Jul 27;14(1):4513. doi: 10.1038/s41467-023-40028-z. Nat Commun. 2023. PMID: 37500647 Free PMC article. Clinical Trial.
Tumor-Infiltrating Myeloid Cells Co-Express TREM1 and TREM2 and Elevated TREM-1 Associates With Disease Progression in Renal Cell Carcinoma.
Ford JW, Gonzalez-Cotto M, MacFarlane AW 4th, Peri S, Howard OMZ, Subleski JJ, Ruth KJ, Haseebuddin M, Al-Saleem T, Yang Y, Rayman P, Rini B, Linehan WM, Finke J, Weiss JM, Campbell KS, McVicar DW. Ford JW, et al. Among authors: macfarlane aw 4th. Front Oncol. 2022 Feb 10;11:662723. doi: 10.3389/fonc.2021.662723. eCollection 2021. Front Oncol. 2022. PMID: 35223446 Free PMC article.
Alterations of NK Cell Phenotype in the Disease Course of Multiple Myeloma.
Pazina T, MacFarlane AW 4th, Bernabei L, Dulaimi E, Kotcher R, Yam C, Bezman NA, Robbins MD, Ross EA, Campbell KS, Cohen AD. Pazina T, et al. Among authors: macfarlane aw 4th. Cancers (Basel). 2021 Jan 10;13(2):226. doi: 10.3390/cancers13020226. Cancers (Basel). 2021. PMID: 33435153 Free PMC article.
Immune phenotype of patients with stage IV metastatic inflammatory breast cancer.
Fernandez SV, MacFarlane AW 4th, Jillab M, Arisi MF, Yearley J, Annamalai L, Gong Y, Cai KQ, Alpaugh RK, Cristofanilli M, Campbell KS. Fernandez SV, et al. Among authors: macfarlane aw 4th. Breast Cancer Res. 2020 Dec 2;22(1):134. doi: 10.1186/s13058-020-01371-x. Breast Cancer Res. 2020. PMID: 33267869 Free PMC article.
Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell Lymphoma.
Barta SK, Zain J, MacFarlane AW 4th, Smith SM, Ruan J, Fung HC, Tan CR, Yang Y, Alpaugh RK, Dulaimi E, Ross EA, Campbell KS, Khan N, Siddharta R, Fowler NH, Fisher RI, Oki Y. Barta SK, et al. Among authors: macfarlane aw 4th. Clin Lymphoma Myeloma Leuk. 2019 Jun;19(6):356-364.e3. doi: 10.1016/j.clml.2019.03.022. Epub 2019 Apr 3. Clin Lymphoma Myeloma Leuk. 2019. PMID: 31029646 Free PMC article. Clinical Trial.
Application of 3D tumoroid systems to define immune and cytotoxic therapeutic responses based on tumoroid and tissue slice culture molecular signatures.
Finnberg NK, Gokare P, Lev A, Grivennikov SI, MacFarlane AW 4th, Campbell KS, Winters RM, Kaputa K, Farma JM, Abbas AE, Grasso L, Nicolaides NC, El-Deiry WS. Finnberg NK, et al. Among authors: macfarlane aw 4th. Oncotarget. 2017 Aug 5;8(40):66747-66757. doi: 10.18632/oncotarget.19965. eCollection 2017 Sep 15. Oncotarget. 2017. PMID: 28977993 Free PMC article.
23 results